Ex parte JANOFF et al. - Page 3




              Appeal No. 1999-0161                                                                                            
              Application 08/441,567                                                                                          


                      50.  A method of reducing false positive results from a lipid-dependent diagnostic                      
              assay performed on a blood sample obtained from a patient having an autoimmune                                  
              disorder characterized by the presence of anti-phospholipid antibodies, which comprises                         
              pre-incubating the sample prior to conducting the assay with an aqueous phase                                   
              comprising a suspended phospholipid, wherein the phospholipid has a hexagonal (Hll)                             
              organization in aqueous detergent free media, wherein the aqueous phase comprises a                             
              detergent, wherein the phospholipid remains suspended in the aqueous phase for at least                         
              one hour at a temperature of about 25 deg. C. and wherein the phospholipid and detergent                        
              are [Sic, not] capable of interfering with the anticoagulant effect of heparin, anti-Factor                     
              antibodies and factor deficiencies.                                                                             
                      61.  A method of determining the presence of lupus anticoagulants in a patient's                        
              plasma which comprises the steps of:                                                                            
                      (a) obtaining a first and a second sample of a patient's plasma;                                        
                      (b) incubating the first sample with an aqueous suspension comprising a                                 
              phosphatidylethanolamine;                                                                                       
                      (c) performing a lipid-dependent diagnostic assay on both the first and the second                      
              sample, the assay producing a positive reading when used on a sample which contains                             
              lupus anticoagulants; and                                                                                       
                      (d) comparing the results of the assays performed on the first and second samples,                      
              the presence of a normal result for the first sample and a positive result for the second                       
              sample being indicative of the presence of lupus anticoagulants in the plasma;                                  
              wherein:                                                                                                        
                      the suspension of the phosphatidylethanolamine further comprises a lupus assay-                         
              compatible detergent;                                                                                           
                      the phosphatidylethanolamine remains in suspension at a temperature of 25AC for at                      
              least one hour;                                                                                                 
                      the detergent, in combination with the phosphatidylethanolamine, is capable of                          
              inhibiting lupus anticoagulant, and not interfering with the anticoagulant effect of heparin,                   
              anti-Factor antibodies and factor deficiencies; and                                                             

                                                              3                                                               





Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  Next 

Last modified: November 3, 2007